A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Số trang: 13
Loại file: pdf
Dung lượng: 802.99 KB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has shown clinical activity as monotherapy in phase I and II studies of advanced cancer.
Nội dung trích xuất từ tài liệu:
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Nội dung trích xuất từ tài liệu:
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Dose-escalation Advanced solid tumors Allosteric MEK1 2 inhibitor Periorbital edemaTài liệu có liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 179 0 0 -
6 trang 171 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 150 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 135 0 0 -
12 trang 103 0 0
-
19 trang 81 0 0
-
17 trang 71 0 0
-
9 trang 48 0 0
-
9 trang 43 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 43 0 0